HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Correspondence: Submit a response Alert me when this article is cited Alert me when Correspondence are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Irving, G. A. Search for Related Content PubMed Articles by Irving, G. A.

Neurology supplements are not peer-reviewed. Information contained in Neurology supplements represent the opinions of the authors and are not endorsed by nor do they reflect the views of the American Academy of Neurology, Editor-in-Chief, or Associate Editors of Neurology.

Contemporary assessment and management of neuropathic pain

From the University of Washington Medical School and the Swedish Pain Center, Seattle, Washington, USA.

Address correspondence to Dr. Gordon A. Irving, Swedish Pain Center, Suite 200, 1101 Madison St., Seattle, WA 98104, USA.

Preclinical studies have increased our understanding of the pathophysiology of neuropathic pain at the anatomic, cellular, and molecular levels. These lines of investigation have enabled more logical uses of older therapies for neuropathic pain and have contributed to our understanding of the potential mechanisms underlying the efficacy of newer remedies. The identification of receptor systems and the development of genetically modified animal models for the study of neuropathic pain have greatly increased our understanding of effective clinical treatments. This review focuses on the central and peripheral nervous system changes believed to be important in the initiation and perpetuation of neuropathic pain. Currently used medications, as well as medications that are on the horizon, are highlighted.

Publication of this supplement was made possible by an educational grant from GlaxoSmithKline. G.A.I. has disclosed no financial relationship with the sponsor.